US Patent Applications in Skin Care Actives and Formulations Published in 2013
US PROVISIONAL PATENT APPLICATIONS IN SKIN CARE ACTIVES PUBLISHED IN 2013
This list includes Provisional Patent Applications published in the United States. The list was retrieved by searching the claims section of all patent applications published. Salient search
terms include skin care active ingredients having properties such as anti-ageing, anti-wrinkle, antioxidant, acne control benefits, skin whitening or lightening, blemish removal, etc. This
category includes technology related to the synthesis and delivery of actives such as peptides, exfoliants, α-hydroxy acids, herbals, free radical scavengers, "green" derived molecules and
compounds having unique sensory properties.

Thank you for visiting FormulaScan . Please click on the Patent No to study the full patent document

US PATENT APPLICATIONS IN SKIN CARE ACTIVES PUBLISHED IN 2013



Application No.: US20130005645A1  Published: 03/Jan/2013

Title: APOE PEPTIDE DIMERS AND USES THEREOF

Applicant/Assignee:

Application No.: 13/520623   Filing Date: 06/Jan/2011

Abstract:

The present invention provides novel pharmaceutical compositions comprising ApoE-derived peptide dimers. In particular, the ApoE peptide dimers of the invention comprise at least two ApoE mimetic domains and can comprise one or more protein transduction domains. Methods of treating various conditions, such as cancer, inflammatory conditions, and neurodegenerative diseases, by administering the pharmaceutical compositions of the invention are also disclosed.

Priority: US2010-292668P Applic. Date: 2010-01-06; WO2011US20393 Applic. Date: 2011-01-06

Inventor: VITEK MICHAEL P [US]; CHRISTENSEN DALE J [US]


Application No.: US20130012449A1  Published: 10/Jan/2013

Title: SOLVENT-FREE PROCESS FOR OBTAINING PHOSPHOLIPIDS AND NEUTRAL ENRICHED KRILL OILS

Applicant/Assignee: THAROS LTD

Application No.: 13/504011   Filing Date: 30/Oct/2009

Abstract:

The invention discloses a new solvent-free process for obtaining phospholipids and neutral lipids enriched krill oils containing DHA and EPA poly-unsaturated fatty acids and astaxanthin. The process includes cooking fresh krill at high temperature-without agitation and or grinding

decanting the cooked krill for obtaining a partial de-fatted and de-watered solid and a liquid

squeezing the obtained solid to obtain a press liquid and a solid fraction

centrifuging the press liquid to obtain the phospholipids enriched krill oil

centrifuging of the decanter liquid obtained to obtain the neutral lipid enriched krill oil and stickwater.

Priority: WO2009IB07269 Applic. Date: 2009-10-30

Inventor: KATEVAS DIMITRI SCLABOS [CL]; TORO GUERRA RAUL R [CL]; CHIONG LAY MARIO M [CL]


Application No.: US20130018000A1  Published: 17/Jan/2013

Title: RECOMBINANT FILAGGRIN POLYPEPTIDES FOR CELL IMPORTATION

Applicant/Assignee: RESEARCH DEVELOPMENT FOUNDATION

Application No.: 13/511267   Filing Date: 22/Nov/2010

Abstract:

Disclosed are recombinant polypeptides that include (a) a filaggrin amino acid sequence and (b) a cell importation signal sequence that includes a motif of two to fifteen amino acids, wherein the motif includes at least one arginine residue and at least one methionine residue. Also disclosed are nucleic acids encoding the recombinant polypeptides of the present invention, and compositions that include the recombinant polypeptides and nucleic acids of the present invention. Methods of treating or preventing a skin disease or skin disorder using the compositions of the present invention are also included, as well as kits that include a sealed containing that includes a recombinant polypeptide of the present invention.

Priority: US2009-263604P Applic. Date: 2009-11-23; WO2010US57592 Applic. Date: 2010-11-22

Inventor: STOUT J TIMOTHY [US]


Application No.: US20130023480A1  Published: 24/Jan/2013

Title: Purified Bowman-Birk Protease Inhibitor Proteins Isolated from a Soy Processing Sttream

Applicant/Assignee: SOLAE, LLC

Application No.: 13/519832   Filing Date: 30/Dec/2010

Abstract:

Purified Bowman-Birk protease inhibitor (BBI) proteins recovered from a soy processing stream are disclosed, as well as a process for recovering and isolating purified BBI proteins from a soy processing stream.

Priority: US2009-291312P Applic. Date: 2009-12-30; WO2010US62553 Applic. Date: 2010-12-30

Inventor: SCHASTEEN CHARLES S [US]; MARSH DARRELL [US]; KELLER KARSTEN [US]; MEKEL MARLENE [US]; WU JENNIFER [US]; TULK BARRY [US]


Application No.: US20130028850A1  Published: 31/Jan/2013

Title: TOPICAL TETRACYCLINE COMPOSITIONS

Applicant/Assignee: FOAMIX LTD

Application No.: 13/499475   Filing Date: 01/Oct/2010

Abstract:

A topical therapeutic hydrophobic breakable composition includes a carrier comprising (a) about 60% to about 99% by weight of at least one hydrophobic oil

(b) at least one viscosity-modifying agents selected from the group consisting of a fatty alcohol, a fatty acid and a wax

and (c) a tetracycline antibiotic, characterized in that at least part of the tetracycline antibiotic is suspended in the composition

the viscosity of the composition is at least about 30% higher than the viscosity of the carrier without the tetracycline antibiotic

and is higher than the viscosity of the hydrophobic oil and the tetracycline antibiotic without the viscosity modifying agents

and the amount of viscosity modifying agents can optionally be reduced by at least an amount by weight that would have increased the viscosity of the carrier without the tetracycline antibiotic by at least 30%

wherein the tetracycline is chemically stable in the composition for at least six months

wherein more than about 90% of the tetracycline has not broken down

wherein when packaged in an aerosol container to which is added a liquefied or compressed gas propellant the composition affords upon release from the container a breakable foam of at least good quality that breaks easily upon application of shear force.

Priority: US2009-248144P Applic. Date: 2009-10-02; US2010-322148P Applic. Date: 2010-04-08; US2010-331126P Applic. Date: 2010-05-04; US2010-349911P Applic. Date: 2010-05-31; US2010-380568P Applic. Date: 2010-09-07; US2010-385385P Applic. Date: 2010-09-22; US2010-388884P Applic. Date: 2010-10-01; WO2010IB02617 Applic. Date: 2010-10-01

Inventor: TAMARKIN DOV [IL]; GAZAL ELANA [IL]; PAPIASHVILI IRAKLIY [IL]; HAZOT YOHAN [IL]; SCHUZ DAVID [IL]; KEYNAN RITA [IL]


Application No.: US20130029902A1  Published: 31/Jan/2013

Title: CXC CHEMOKINE RECEPTOR 4 (CXCR4) ANTAGONISTIC POLYPEPTIDE

Applicant/Assignee:

Application No.: 12/452480   Filing Date: 03/Jul/2008

Abstract:

A peptide having the following amino acid sequence: Z1-LVRYTKKVPQVSTPTL-Z2(ALB-408) and its biologically active fragments and/or variants and/or derivatives, especially amidated, acetylated, sulfated, phosphorylated and/or glycosylated derivatives, and peptides obtainable by multiple synthesis which have the biological activity of ALB408-423

wherein Z represents number of from 0 to 10 amino acid residues.

Priority: DE20071030904 Applic. Date: 2007-07-03; WO2008EP58566 Applic. Date: 2008-07-03

Inventor: FORSSMANN WOLF-GEORG [DE]; KIRCHHOFF FRANK [DE]; MUENCH JAN [DE]; STAENDKER LUDGER [DE]


Application No.: US20130034523A1  Published: 07/Feb/2013

Title: USE OF SDF-1 TO MITIGATE SCAR FORMATION

Applicant/Assignee: JUVENTAS THERAPEUTICS, INC, THE CLEVELAND CLINIC FOUNDATION

Application No.: 13/650726   Filing Date: 12/Oct/2012

Abstract:

The subject matter provided herein relates to method for inhibiting or mitigating scar formation in a wound of the skin, by increasing the concentration of SDF-1 in, or proximate to, the wound. As described herein SDF-1 protein or an SDF-1 expression vector can be administered to a wound or the area proximate a wound by providing a therapeutically effective amount of SDF-1 protein or an SDF-1 expression vector.

Priority: US2010-808056 Applic. Date: 2010-06-14; WO2008US86820 Applic. Date: 2008-12-15; US2007-013878P Applic. Date: 2007-12-14

Inventor: PENN MARC S [US]; ARAS RAHUL [US]; KIEDROWSKI MATTHEW [US]; PASTORE JOSEPH [US]


Application No.: US20130039903A1  Published: 14/Feb/2013

Title: ECZEMA TREATMENT

Applicant/Assignee: PROBIOTEC LIMITED

Application No.: 13/641191   Filing Date: 21/Apr/2011

Abstract:

A use of a composition including lactoferrin and/or immunoglobulin for minimizing the severity of one or more symptoms associated with eczema.

Priority: AU20100901718 Applic. Date: 2010-04-23; WO2011AU00467 Applic. Date: 2011-04-21

Inventor: GANTER RUDI [AU]; AHMAD HUMERA [AU]


Application No.: US20130039918A1  Published: 14/Feb/2013

Title: Pharmaceutical Composition Using Connective-tissue Growth Factor

Applicant/Assignee: POSTECH ACADEMY-INDUSTRY FOUNDATION

Application No.: 13/642143   Filing Date: 21/Feb/2011

Abstract:

This disclosure relates to an angiogenesis-related pharmaceutical composition using connective tissue growth factor, more particularly to a pharmaceutical composition for promoting angiogenesis containing the connective tissue growth factor or a pharmaceutical composition for inhibiting angiogenesis containing at least one selected from the group consisting of polypeptide, antibody and a compound binding to connective tissue growth factor. The fragment of connective tissue growth factor protein, which was found out in the present invention, is a binding region to FPRL1, effectively induces FPRL1-specific ERK phosphorylation, activates FPRL1 to increase intracellular Ca2+ concentration, and finally, effectively induces angiogenesis, and thus, the fragment of connective tissue growth factor may be useful for a pharmaceutical composition for promoting angiogenesis, while polypeptide, antibody or a compound binding to the fragment of connective tissue growth factor protein may be useful for a pharmaceutical composition for inhibiting angiogenesis.

Priority: KR20100132775 Applic. Date: 2010-12-22; US2010-328686P Applic. Date: 2010-04-28; WO2011KR01125 Applic. Date: 2011-02-21

Inventor: RYU SUNG HO [KR]; SUH PANN-GHILL [KR]; LEE MI-SOOK [KR]; KIM WAN-UK [KR]


Application No.: US20130045267A1  Published: 21/Feb/2013

Title: METHODS OF USING AGENTS THAT MODULATE CLAUDIN EXPRESSION

Applicant/Assignee: UNIVERSITY OF ROCHESTER

Application No.: 13/576959   Filing Date: 07/Feb/2011

Abstract:

Methods are provided for modulating expression of claudin-1 and/or claudin-23, for purposes of regulating formation of tight junctions in keratinocytes or other types of cells such as antigen presenting cells (e.g., dendritic cells and Langertians cells), by either increasing or decreasing expression of claudin-1 and/or claudin-23. Also provided are transdermal formulations that decrease expression of claudin-1 and/or claudin-23, thereby diminishing tight junction formation in cells expressing claudin-1 and/or claudin-23, as well as a transdermal patch for delivering the same.

Priority: US2010-302022P Applic. Date: 2010-02-05; WO2011US23951 Applic. Date: 2011-02-07

Inventor: BECK LISA A [US]; DE BENEDETTO ANNA [US]


Application No.: US20130045918A1  Published: 21/Feb/2013

Title: Methods for Treating Diabetic Wounds

Applicant/Assignee: CALREGEN INC, NEW YORK UNIVERSITY

Application No.: 13/367039   Filing Date: 06/Feb/2012

Abstract:

The present invention relates to a method of treating chronic wounds using calreticulin. In particular, the invention relates to the treatment of chronic diabetic wounds using topical application of calreticulin to a patient in need of such treatment.

Priority: US2009-547256 Applic. Date: 2009-08-25; US2008-091648P Applic. Date: 2008-08-25

Inventor: GOLD LESLIE I [US]; MICHALAK MAREK [CA]


Application No.: US20130052245A1  Published: 28/Feb/2013

Title: COSMETIC AND DERMATOLOGICAL FORMULATIONS OF MNTF PEPTIDES

Applicant/Assignee: DERMACARE NEUROSCIENCE INSTITUTE

Application No.: 13/659782   Filing Date: 24/Oct/2012

Abstract:

The disclosure is directed to methods and compositions that include MNTF peptides and their analogs for cosmetic and dermatological purposes.

Priority: US2009-391243 Applic. Date: 2009-02-23; US2008-066670P Applic. Date: 2008-02-21

Inventor: KO PUI-YUK DOROTHY [US]


Application No.: US20130053303A1  Published: 28/Feb/2013

Title: COMPOUNDS FOR ENZYME INHIBITION

Applicant/Assignee: ONYX THERAPEUTICS, INC

Application No.: 13/646491   Filing Date: 05/Oct/2012

Abstract:

One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.

Priority: US201113328909 Applic. Date: 2011-12-16; US2010-708753 Applic. Date: 2010-02-19; US2007-820490 Applic. Date: 2007-06-19; US2006-815218P Applic. Date: 2006-06-19

Inventor: SHENK KEVIN D [US]; PARLATI FRANCESCO [US]; ZHOU HAN-JIE [US]; SYLVAIN CATHERINE [US]; SMYTH MARK S [US]; BENNETT MARK K [US]; LAIDIG GUY J [US]


Application No.: US20130059790A1  Published: 07/Mar/2013

Title: PROCESS FOR THE PREPARATION OF A BIOMASS COMPRISING PLANTARICIN AND USES THEREOF IN MEDICAL FIELD

Applicant/Assignee: GIULIANI S.P.A

Application No.: 13/521695   Filing Date: 04/Jan/2011

Abstract:

The present invention concerns a process for preparation of a biomass comprising one or a more plantaricins A, N or K in association with the lactic acid bacteria used for the preparation and uses thereof in order to stimulate the barrier function of intestinal cells or human epidermal keratinocytes.

Priority: IT2010RM00004 Applic. Date: 2010-01-12; WO2011IT00003 Applic. Date: 2011-01-04

Inventor: GIULIANI GIAMMARIA [IT]; BENEDUSI ANNA [IT]; GOBBETTI MARCO [IT]; DI CAGNO RAFFAELLA [IT]; DE ANGELIS MARIA [IT]; CALASSO MARIA [IT]


Application No.: US20130065816A1  Published: 14/Mar/2013

Title: ANALOGS OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND METHODS FOR THEIR USE

Applicant/Assignee: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND

Application No.: 13/505370   Filing Date: 02/Nov/2010

Abstract:

This invention relates to novel analogs of pituitary adenylate cyclase-activating polypeptide (PACAP), which are agonists for the PACAP/vasoactive intestinal peptide (VIP) receptors: PAC1, VPAC1 and VPAC2 receptors. These PACAP analogs can be used as prophylactic/therapeutic agents for a wide range of medical disorders, including (but not limited to) cancer and autoimmune disease. These PACAP analogs can be coupled to suitable radionuclides and used in the localization, diagnosis and treatment of disseminated cancers and metastatic tumors, or coupled to small molecule therapeutics and used as vectors for targeted drug delivery. This invention also provides pharmaceutical compositions of one or more PACAP-like compounds of the invention either alone or in combination with one or more other prophylactic/therapeutic agents.

Priority: US2009-280298P Applic. Date: 2009-11-02; WO2010US55164 Applic. Date: 2010-11-02

Inventor: COY DAVID H [US]; MADERDRUT JEROME L [US]; LI MIN [US]


Application No.: US20130065827A1  Published: 14/Mar/2013

Title: Crystalline Peptide Epoxyketone Immunoproteasome Inhibitor

Applicant/Assignee:

Application No.: 13/639087   Filing Date: 06/Apr/2011

Abstract:

The invention relates to crystalline peptide keto epoxide compounds, methods of their preparation, and related pharmaceutical compositions.

Priority: US2010-321577P Applic. Date: 2010-04-07; WO2011US31436 Applic. Date: 2011-04-06

Inventor: PHIASIVONGSA PASIT [US]


Application No.: US20130065835A1  Published: 14/Mar/2013

Title: PROGNOSTIC TESTS FOR DEVELOPMENT OF DERMAL STRETCH MARKS AND IMPLICATIONS FOR THE PREVENTATIVE TREATMENT THEREOF

Applicant/Assignee: THE HOSPITAL FOR SICK CHILDREN, HUMAN MATRIX SCIENCES, LLC

Application No.: 13/671531   Filing Date: 07/Nov/2012

Abstract:

Various methods of assessing the regenerative potential of dermal tissue in a patient may be determined and methods to determine the potential development of stretch marks in a patient are provided. Through the analysis of a series of dermal tissue samples, a method of monitoring the aging process of the dermal tissue of a patient is possible. Damaged or stretched marked skin may also be used in the development of various diagnostic therapies relating to the inducement of the extracellular matrix components of the skin due to the loss of elastic fibers generally found in stretch marked skin.

Priority: US2010-825207 Applic. Date: 2010-06-28; US2005-141635 Applic. Date: 2005-05-31; US2004-575737P Applic. Date: 2004-05-28

Inventor: MITTS THOMAS [US]; JIMENEZ FELIPE [US]; HINEK ALEKSANDER [CA]


Application No.: US20130072421A1  Published: 21/Mar/2013

Title: TREATMENT OF SIRTUIN (SIRT) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A SIRTUIN (SIRT)

Applicant/Assignee: CURNA, INC

Application No.: 13/695801   Filing Date: 13/Jan/2011

Abstract:

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Sirtuin (SIRT), in particular, by targeting natural antisense polynucleotides of a Sirtuin (SIRT). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Sirtuins (SIRT)s.

Priority: US2010-330427P Applic. Date: 2010-05-03; US2010-415891P Applic. Date: 2010-11-22; US2010-412066P Applic. Date: 2010-11-10; US2010-409136P Applic. Date: 2010-11-02; WO2011US21052 Applic. Date: 2011-01-13

Inventor: COLLARD JOSEPH [US]; KHORKOVA SHERMAN OLGA [US]; COITO CARLOS [US]; DE LEON BELINDA [US]


Application No.: US20130072425A1  Published: 21/Mar/2013

Title: SAPOSIN-A DERIVED PEPTIDES AND USES THEREOF

Applicant/Assignee: CHILDREN'S MEDICAL CENTER CORPORATION

Application No.: 13/516511   Filing Date: 17/Dec/2010

Abstract:

The invention relates to isolated peptides and chimeric polypeptides derived from Saposin A that have anti-angiogenic activity. These peptides are small, consisting essentially of at least 10 consecutive amino acid residues from the 31st-50th amino acid residue of Saposin A. The invention also relates to the use of these isolated peptides and chimeric polypeptides in compositions for the treatment, prevention, and inhibition of angiogenesis-related diseases and disorders such as cancer and cancer metastasis.

Priority: US2009-640788 Applic. Date: 2009-12-17; WO2008US67899 Applic. Date: 2008-06-23; US2007-936792P Applic. Date: 2007-06-22; WO2010US61007 Applic. Date: 2010-12-17

Inventor: WATNICK RANDOLPH [US]


Application No.: US20130072445A9  Published: 21/Mar/2013

Title: DEVELOPMENT OF C-REACTIVE PROTEIN MUTANT WITH IMPROVED THERAPEUTIC BENEFIT IN IMMUNE THROMBOCYTOPENIA AND LUPUS NEPHRITIS

Applicant/Assignee:

Application No.: 12/995828   Filing Date: 02/Jun/2009

Abstract:

The present invention relates to the use of a mutant CRP molecule in which tyrosine 175 is replaced by leucine (Y175L CRP) or the leucine 176 is replaced by glutamic acid (L176E CRP) for the treatment of various disease states and conditions associated with SLE, including lupus of the skin (discoid), systemic lupus of the joints, lungs and kidneys, hematological conditions including hemolytic anemia and low lymphocyte counts, lymphadenopathy and CNS effects, including memory loss, seizures and psychosis, among numerous others as otherwise disclosed herein. In another aspect of the invention, the reduction in the likelihood that a patient who is at risk for an outbreak of a disease state or condition associated with SLE will have an outbreak is an additional aspect of the present invention.

The present invention relates to the use of mutant Y175L CRP or L176E CRP in the treatment of a number of disease states or conditions that occur secondary to systemic lupus SLE. The present invention also relates to the treatment of immune thrombocytopenic purpura. Pharmaceutical compositions are also disclosed based these mutant CRP molecules.

Priority: US2008-083055 Applic. Date: 2008-08-11; WO2006US41583 Applic. Date: 2006-10-26; US2005-730013P Applic. Date: 2005-10-26; US2008-130749P Applic. Date: 2008-06-03; WO2009US03338 Applic. Date: 2009-06-02

Inventor: DU CLOS TERRY W [US]; MOLD CAROLYN [US]


Application No.: US20130089514A1  Published: 11/Apr/2013

Title: Stem cell secreted product derived compositions for wound treatment

Applicant/Assignee:

Application No.: 13/688796   Filing Date: 29/Nov/2012

Abstract:

Compositions including formulations comprising secreted products obtained from the culture medium of stem cells, such as umbilical cord blood stem cells, or embryonic germ cell derivatives, or embryonic stem cells, are provided for enhancement of wound healing. Further compositions contain components identified in such culture medium to enhance wound healing. Methods for using the compositions and formulations for enhancing wound healing are also provided. Wounds to both soft and bony tissues are encompassed, and include wounds created by surgical procedures.

Priority: US2010-448436 Applic. Date: 2010-02-02; WO2007US25836 Applic. Date: 2007-12-19; US2006-875560P Applic. Date: 2006-12-19

Inventor: COHEN MICHAEL [US]; COHEN JACOB [US]


Application No.: US20130095058A1  Published: 18/Apr/2013

Title: ANTIMICROBIAL COMBINATIONS OF PYRION COMPOUNDS WITH POLYETHYLENEIMINES

Applicant/Assignee: JANSSEN PHARMACEUTICA NV

Application No.: 13/805013   Filing Date: 29/Jun/2011

Abstract:

The present invention relates to combinations of the pyrion compounds sodium pyrithione and 1-hydroxy-2-pyridinone, and polyethyleneimines (PEI) which provide an improved biocidal effect. More particularly, the present invention relates to compositions comprising a combination of a pyrion compound selected from sodium pyrithione and 1-hydroxy-2-pyridinone together with polyethyleneimines

in respective proportions to provide a synergistic biocidal effect. Compositions comprising these combinations are useful for the protection of any living or non-living material, such as crops, plants, fruits, seeds, objects made of wood, thatch or the like, engineering material, biodegradable material and textiles against deterioration due to the action of microorganisms such as bacteria, fungi, yeasts, algae, viruses, and the like.

Priority: EP20100168111 Applic. Date: 2010-07-01; WO2011EP60874 Applic. Date: 2011-06-29

Inventor: BYLEMANS DANY LEOPOLD JOZEFIEN [BE]; DE BOLLE MIGUEL F C [NL]


Application No.: US20130101540A1  Published: 25/Apr/2013

Title: AQUEOUS DISPERSIONS OF POLYURETHANE AND NANOPARTICLES

Applicant/Assignee: BAYER MATERIALSCIENCE LLC

Application No.: 13/278274   Filing Date: 21/Oct/2011

Abstract:

The present disclosure is directed to aqueous dispersions comprising polyurethane and nanoparticles, and processes for preparing the aqueous dispersions. The dispersions comprise aqueous polyurethane dispersions having nanoparticles covalently incorporated into the polymer matrix. The dispersions are prepared by reacting isocyanate groups present on the polyurethane chain ends with free amine groups on a hydroxy- or amino-functionalized nanoparticle to covalently attach the polyurethane and the nanoparticle through urethane or urea linkages, respectively.

Priority:

Inventor: UNAL SERKAN [US]; BEREZKIN YULIYA [US]; SCHMITT PETER D [US]; HAIDER KARL W [US]; HUNT ROBERT N [US]


Application No.: US20130101662A1  Published: 25/Apr/2013

Title: PEPTIDES USED IN THE TREATMENT AND/OR CARE OF THE SKIN, MUCOUS MEMBRANES AND/OR HAIR AND ITS USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS

Applicant/Assignee: BCN PEPTIDES S.A, LIPOTEC, S.A

Application No.: 13/502274   Filing Date: 22/Oct/2010

Abstract:

Peptides of general formula (I): R1-Wn-Xm-AA1-AA2-AA3-AA4-Yp-Zq-R2 (I) its stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, a preparation process, cosmetic or pharmaceutical compositions which contain them and their use in the treatment and/or care of the skin, mucous membranes and/or hair and the treatment and/or care of those conditions, disorders and/or diseases which are improved or prevented by Hsp stimulation.

Priority: ES20090030896 Applic. Date: 2009-10-23; US2009-254340P Applic. Date: 2009-10-23; WO2010EP06454 Applic. Date: 2010-10-22

Inventor: CARRENO RAIMA CRISTINA [ES]; VAN DEN NEST WIM [ES]; SEMPERE BONETE ANA [ES]; FERRER MONTIEL ANTONIO [ES]; ALMINANA DOMENECH NURIA [ES]; CEBRIAN PUCHE JUAN [ES]


Application No.: US20130108602A1  Published: 02/May/2013

Title: METHODS AND USES OF NUR77 AND NUR77 AGONISTS TO MODULATE MACROPHAGES AND MONOCYTES, AND TREAT INFLAMMATION, INFLAMMATORY DISEASE AND CARDIOVASCULAR DISEASE

Applicant/Assignee: LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY, LA JOLLA INSTITUTE FOR ALLERGY AND IMMU

Application No.: 13/646183   Filing Date: 05/Oct/2012

Abstract:

Methods of decreasing, reducing, inhibiting, suppressing, limiting or controlling an undesirable or aberrant immune response, immune disorder, inflammatory response, or inflammation in a subject

decreasing, reducing, inhibiting, suppressing, limiting or controlling an autoimmune response, disorder or disease in a subject

and decreasing, reducing, inhibiting, suppressing, limiting or controlling an adverse cardiovascular event or cardiovascular disease in a subject, are provided. Methods include, for example, administering a Nur77 polypeptide or subsequence thereof, a Nur77 agonist, or CD14+ CD16+ monocytes or CD14dimCD16+ (CD115+CD11b+GR1- (Ly6C-)) monocytes or macrophages to a subject to decrease, reduce, inhibit, suppress, limit or control the underlying condition or an adverse symptom or pathology of the condition.

Priority: WO2011US31585 Applic. Date: 2011-04-07; US2010-321781P Applic. Date: 2010-04-07; US2010-391267P Applic. Date: 2010-10-08

Inventor: HEDRICK CATHERINE C [US]; LEY KLAUS [US]; HANNA RICHARD [US]; SHAKED IFTACH [US]


Application No.: US20130108614A1  Published: 02/May/2013

Title: WOUND HEALING PEPTIDES AND METHODS OF USE THEREOF

Applicant/Assignee: TUFTS UNIVERSITY

Application No.: 13/652889   Filing Date: 16/Oct/2012

Abstract:

The current invention relates to methods and compositions for the treatment of wounds in a mammalian subject. Particularly, the invention relates to novel polypeptides and encoding nucleic acids that stimulate keratinocyte and endothelial cell motility and/or proliferation.

Priority: US2010-811124 Applic. Date: 2010-07-16; WO2009US30463 Applic. Date: 2009-01-08; US2008-010401P Applic. Date: 2008-01-08

Inventor: HERMAN IRA M [US]


Application No.: US20130109614A1  Published: 02/May/2013

Title: ANTAGONISTS FOR DISEASES INDUCED BY CELLS WITH HIGH-AFFINITY ELR-CXC CHEMOKINE RECEPTOR PROTEINS

Applicant/Assignee: NATIONAL TSING HUA UNIVERSITY

Application No.: 13/494587   Filing Date: 12/Jun/2012

Abstract:

Enclosed is an antagonist, which includes a peptide chain represented by an amino acid sequence. The amino acid sequence has a short sequence, C-X1X2X3X4X5-N, which is situated before and neighbored to the third cysteine (Cys, C) of the N-terminus, wherein X1 is an amino acid with aromatic ring, hydrophobic property or long chain, and X2, X3, X4 and X5 are glutamine (G), serine (S), alanine (A) and proline (P) respectively. In one embodiment, X1 is phenylalanine (F). The present antagonists can be used to inhibit or treat with the diseases caused by the activated cells expressing CXCR1 and/or CXCR2 receptor, for example, the acute or chronic inflammatory reaction induced with polymorphonuclear neutrophils (PMNs) expressing CXCR1 and/or CXCR2 receptor, and angiogenesis accompanied by tumor growth inhibition.

Priority: TW20110138960 Applic. Date: 2011-10-26

Inventor: CHENG JYA-WEI [TW]; HUANG KUO-CHUN [TW]; CHENG HSI-TSUNG [TW]; YU HUI-YUAN [TW]


Application No.: US20130121951A1  Published: 16/May/2013

Title: LUBRICIOUS AQUEOUS COMPOSITION

Applicant/Assignee: INOFLEX AB

Application No.: 13/512852   Filing Date: 30/Nov/2010

Abstract:

Disclosed is a lubricious aqueous composition comprising at least one thickener and at least one compound forming a shear-thickening fluid when mixed with water. Such a lubricious aqueous composition is useful as sex lubricant.

Priority: EP20090177537 Applic. Date: 2009-11-30; WO2010EP68504 Applic. Date: 2010-11-30

Inventor: STERN LEIF EINAR [SE]


Application No.: US20130123190A1  Published: 16/May/2013

Title: Methods for Treating Combined Radiation and Thermal Injury

Applicant/Assignee: UNIVERSITY OF SOUTHERN CALIFORNIA

Application No.: 13/637038   Filing Date: 28/Mar/2011

Abstract:

The present invention provides methods for treating a subject that has suffered combined exposure to total body ionizing irradiation and burns.

Priority: US2010-317897P Applic. Date: 2010-03-26; WO2011US30142 Applic. Date: 2011-03-28

Inventor: RODGERS KATHLEEN E [US]; DIZEREGA GERE S [US]


Application No.: US20130129661A1  Published: 23/May/2013

Title: MATERIAL FOR SKIN AND METHOD FOR PRODUCING MATERIAL FOR SKIN

Applicant/Assignee: TORAY INDUSTRIES, INC

Application No.: 13/582139   Filing Date: 01/Mar/2011

Abstract:

A material for skin is provided including a silicone component-containing polymer obtained by polymerizing a silicone monomer having a carbon-carbon double bond, and a component selected from an antibacterial agent and an alcohol. Provided are a material for skin, which is transparent and has a moderate moisture content, and also has high oxygen permeability, and a method for producing the same.

Priority: JP20100045038 Applic. Date: 2010-03-02; JP20100292169 Applic. Date: 2010-12-28; WO2011JP54583 Applic. Date: 2011-03-01

Inventor: KITAGAWA RUMIKO [JP]; NAKAMURA MASATAKA [JP]; KUSUDA SATOSHI [JP]


Application No.: US20130149248A1  Published: 13/Jun/2013

Title: AVss6 PEPTIDE LIGANDS AND THEIR USES

Applicant/Assignee: CANCER RESEARCH TECHNOLOGY LIMITED

Application No.: 13/743714   Filing Date: 17/Jan/2013

Abstract:

AVbeta6 peptide ligands, functional variants thereof and their nucleic acids encoding them are disclosed with their uses in the treatment and imaging of AVbeta6 mediated diseases.

Priority: GB20050020068 Applic. Date: 2005-10-03; US2008-088998 Applic. Date: 2008-11-25; WO2006GB03673 Applic. Date: 2006-10-03

Inventor: HOWARD MARK J [GB]; DICARA DANIELLE [GB]; MARSHALL JOHN [GB]


Application No.: US20130150285A1  Published: 13/Jun/2013

Title: THERAPEUTIC AND COSMETIC USES AND APPLICATIONS OF CALRETICULIN

Applicant/Assignee: CALREGEN INC, NEW YORK UNIVERSITY

Application No.: 13/717349   Filing Date: 17/Jun/2011

Abstract:

Therapeutic and cosmetic uses and applications of calreticulin are provided. In particular, the invention relates to therapeutic and cosmetic uses and applications of calreticulin to a patient in need of such treatment including in tissue repair, wound healing, ulcers, reducing scar formation, and reducing or eliminating wrinkles.

Priority: US2010-355987P Applic. Date: 2010-06-17; WO2011US40979 Applic. Date: 2011-06-17

Inventor: GOLD LESLIE I [US]; MICHALAK MAREK [CA]


Application No.: US20130164242A1  Published: 27/Jun/2013

Title: Polymers And Compositions

Applicant/Assignee: LUBRIZOL ADVANCED MATERIALS, INC

Application No.: 13/819875   Filing Date: 01/Sep/2011

Abstract:

The present invention relates to hair care and personal care compositions which contain an acrylic copolymer which is polymerized in the presence of at least two different classes of crosslinking monomers. The polymer functions both as a fixative/film former and a thickening agent for hair styling and personal care compositions in which it is contained. The copolymer exhibits advantageous fixative, film forming and rheological gel properties.

Priority: US2010-379488P Applic. Date: 2010-09-02; WO2011US50196 Applic. Date: 2011-09-01

Inventor: TAMARESELVY KRISHNAN [US]; STAELENS PASCAL [BE]


Application No.: US20130171180A1  Published: 04/Jul/2013

Title: DERIVATIVES OF GLYCO-CF2-SERINE AND GLYCO-CF2-THREONINE

Applicant/Assignee: TFCHEM

Application No.: 13/823237   Filing Date: 22/Dec/2011

Abstract:

The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof, a tautomer, a stereoisomer or a mixture of stereoisomers in any proportion, in particular a mixture of enantiomers, and particularly a racemate mixture, as well as to their process of preparation, their use in the peptide synthesis, said peptide and the use of said peptide.

Priority: EP20100306493 Applic. Date: 2010-12-22; WO2011EP73822 Applic. Date: 2011-12-22

Inventor: DELIENCOURT-GODEFROY GERALDINE [FR]; FILLON HYACINTHE [FR]; MARTIN THIBAUT [FR]


Application No.: US20130172232A1  Published: 04/Jul/2013

Title: CYSTEINE PROTEASE INHIBITORS

Applicant/Assignee: MEDIVIR UK LTD

Application No.: 13/704441   Filing Date: 16/Jun/2011

Abstract:

Compounds of the formula I wherein R2a and R2b are independently H, halo, C1-C4alkyl, C1-C4haloalkyl or C1-C4alkoxy, or R2a and R2b together with the carbon atom to which they are attached form a C3-C6cycloalkyl

R3 is a C5-C10 alkyl, optionally substituted with 1-3 substituents independently selected from halo, C1-C4haloalkyl, C1-C4alkoxy, C1-C4haloalkoxy

or R3 is a C2-C4alkyl chain with at least 2 chloro or 3 fluoro substituents

or R3 is C3-C7cycloalkylmethyl, optionally substituted with 1-3 substituents independently selected from C1-C4alkyl, halo, C1-C4haloalkyl, C1-C4alkoxy, C1-C4haloalkoxy

R4 is C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkylamino, C1-C6dialkylamino or

R4 is Het or Carbocyclyl, either of which is optionally substituted with 1-3 substituents R4 is Het, carbocyclyl, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy or C1-C6haloalkoxy

n is 1, 2 or 3

for the use in the prophylaxis or treatment of a disorder characterised by inappropriate expression or activation of cathepsin S.

Priority: SE20100050618 Applic. Date: 2010-06-16; WO2011IB52613 Applic. Date: 2011-06-16

Inventor: AYESA SUSANA [SE]; GRABOWSKA URSZULA [SE]; HEWITT ELLEN [SE]; JONSSON DANIEL [SE]; KLASSON BJORN [SE]; KAHNBERG PIA [SE]; LUNDGREN STINA [SE]; TEJBRANT JAN [SE]; WIKTELIUS DANIEL [SE]


Application No.: US20130184220A1  Published: 18/Jul/2013

Title: TREATMENT OF ABNORMAL OR EXCESSIVE SCARS

Applicant/Assignee:

Application No.: 12/809986   Filing Date: 22/Dec/2008

Abstract:

Methods and compositions comprising combinations and uses of a first anti-connexin agent and a second anti-connexin agent, for example, one or more anti-connexin polynucleotides and one or more anti-connexin peptides or peptidomimetics, are provided for the treatmen or prevention of abnormal or excessive scarring.

Priority: US2007-008837P Applic. Date: 2007-12-21; WO2008US14025 Applic. Date: 2008-12-22

Inventor: DUFT BRADFORD JAMES [US]


Application No.: US20130189363A1  Published: 25/Jul/2013

Title: BETA-HAIRPIN PEPTIDOMIMETICS

Applicant/Assignee: UNIVERSITAET ZUERICH, POLYPHOR AG

Application No.: 13/814398   Filing Date: 05/Aug/2010

Abstract:

beta-Hairpin peptidomimetics of the general formula Cyclo (-Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11-Xaa12-Xaa13-Xaa14-), enantiomers and pharmaceutically acceptable salts thereof, with Xaa1-Xaa14 being amino acid residues of certain types which are defined in the description and the claims, have anti-infective activity, e.g. to selectively inhibit the growth of or to kill microorganisms such as Bacillus subtilis and/or Shigella boydii. They can be used as medicaments to treat or prevent infections or as disinfectants for foodstuffs, cosmetics, medicaments or other nutrient-containing materials. These peptidomimetics can be manufactured by a process which is based on a mixed solid- and solution phase synthetic strategy.

Priority: WO2010EP61445 Applic. Date: 2010-08-05

Inventor: OBRECHT DANIEL [CH]; GOMBERT FRANK OTTO [CH]; ROBINSON JOHN ANTHONY [CH]; PATORA-KOMISARSKA KRYSTYNA [CH]


Application No.: US20130195789A1  Published: 01/Aug/2013

Title: LOW SWELL, LONG-LIVED HYDROGEL SEALANT

Applicant/Assignee: ACTAMAX SURGICAL MATERIALS LLC

Application No.: 13/803427   Filing Date: 14/Mar/2013

Abstract:

A low swell, long-lived hydrogel sealant formed by reacting a highly oxidized polysaccharide containing aldehyde groups with a multi-arm amine is described. The hydrogel sealant may be particularly suitable for applications requiring low swell and slow degradation, for example, ophthalmic applications such as sealing wounds resulting from trauma such as corneal lacerations, or from surgical procedures such as vitrectomy procedures, cataract surgery, LASIK surgery, glaucoma surgery, and corneal transplants

neurosurgery applications, such as sealing the dura

and as a plug to seal a fistula or the punctum. The low swell, long-lived hydrogel sealant may also be useful as a tissue sealant and adhesive, and as an anti-adhesion barrier.

Priority: US2009-497729 Applic. Date: 2009-07-06; US2008-135172P Applic. Date: 2008-07-17

Inventor: LU HELEN S M [US]


Application No.: US20130196899A1  Published: 01/Aug/2013

Title: SYNTHETIC APELIN MIMETICS FOR THE TREATMENT OF HEART FAILURE

Applicant/Assignee: NOVARTIS AG

Application No.: 13/747621   Filing Date: 23/Jan/2013

Abstract:

The invention provides a synthetic polypeptide of Formula I': or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Priority: US201261731697P Applic. Date: 2012-11-30; US201261717760P Applic. Date: 2012-10-24; US201261591557P Applic. Date: 2012-01-27

Inventor: ZECRI FREDERIC [US]; GOLOSOV ANDREI [US]; GROSCHE PHILIPP [DE]; YASOSHIMA KAYO [US]; ZHAO HONGJUAN [US]; HU QI-YING [US]; IMASE HIDETOMO [US]; PARKER DAVID THOMAS [US]


Application No.: US20130203650A1  Published: 08/Aug/2013

Title: POLYPEPTIDES DERIVED FROM ALPHA-1 ANTITRYPSIN AND METHODS OF USE THEREOF

Applicant/Assignee: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREWUVIVERSITY OF JERUSALEM

Application No.: 13/819669   Filing Date: 30/Aug/2011

Abstract:

The present invention relates to isolated polypeptides comprising the amino acid sequence of residues 378-413 of Mus musculus alpha-1-antitrypsyn (serpina1c), and active fragments thereof, and to pharmaceutical compositions comprising same. The compositions of the invention are useful for treating burns, inflammatory, autoimmune and degenerative diseases.

Priority: US2010-378414P Applic. Date: 2010-08-31; US201061425038P Applic. Date: 2010-12-20; WO2011IL00696 Applic. Date: 2011-08-30

Inventor: WORMSER URI [IL]


Application No.: US20130209463A1  Published: 15/Aug/2013

Title: POLYPEPTIDES AND USES THEREOF AS A DRUG FOR TREATMENT OF MULTIPLE SCLEROSIS, RHEUMATOID ARTHRITIS AND OTHER AUTOIMMUNE DISORDERS

Applicant/Assignee: COMPUGEN LTD

Application No.: 13/806841   Filing Date: 30/Jun/2011

Abstract:

This invention relates to a protein C1ORF32 and its variants and fragments and fusion proteins thereof, and methods of use thereof for immunotherapy, and drug development, including but not limited to as immune modulators and for immune therapy, including for autoimmune disorders.

Priority: US2010-360011P Applic. Date: 2010-06-30; WO2011IB52877 Applic. Date: 2011-06-30

Inventor: ROTMAN GALIT [IL]; HECHT IRIS [IL]; LEVINE ZURIT [IL]; PODOJIL JOSEPH R [US]; MILLER STEPHEN D [US]


Application No.: US20130209486A1  Published: 15/Aug/2013

Title: GENETIC POLYMORPHISMS ASSOCIATED WITH PSORIASIS, METHODS OF DETECTION AND USES THEREOF

Applicant/Assignee: CELERA CORPORATION

Application No.: 13/657215   Filing Date: 22/Oct/2012

Abstract:

The present invention is based on the discovery of genetic polymorphisms that are associated with psoriasis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, including groups of nucleic acid molecules that may be used as a signature marker set, such as a haplotype, a diplotype, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.

Priority: US201113080458 Applic. Date: 2011-04-05; US2008-325832 Applic. Date: 2008-12-01; US2007-005018P Applic. Date: 2007-11-30

Inventor: LI YONGHONG [US]; SCHRODI STEVEN [US]; BEGOVICH ANN [US]; CHANG MONICA [US]; CARGILL MICHELE [US]


Application No.: US20130216539A1  Published: 22/Aug/2013

Title: Methods of Generation and Treatment with Modified Derivatives of HSP 70

Applicant/Assignee: ALS BIOPHARMA, LLC

Application No.: 13/768242   Filing Date: 15/Feb/2013

Abstract:

The present invention includes methods of generating derivatives of a protein, as well as methods of treating a subject with the derivatized proteins. More particularly, the present invention includes methods of generating derivatives of HSP 70 proteins and methods of treating a subject with the derivatized HSP 70 proteins.

Priority: US201261599632P Applic. Date: 2012-02-16

Inventor: REITZ ALLEN B [US]; PAWLYK AARON [US]; ILYIN SERGEY [US]


Application No.: US20130216551A1  Published: 22/Aug/2013

Title: GENETIC POLYMORPHISMS ASSOCIATED WITH PSORIASIS, METHDOS OF DETECTION AND USES THEREOF

Applicant/Assignee: CELERA CORPORATION

Application No.: 13/712430   Filing Date: 12/Dec/2012

Abstract:

The present invention is based on the discovery of genetic polymorphisms that are associated with psoriasis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, including groups of nucleic acid molecules that may be used as a signature marker set, such as a haplotype, a diplotype, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.

Priority: US201113175159 Applic. Date: 2011-07-01; US2007-899017 Applic. Date: 2007-08-31; US2007-928625P Applic. Date: 2007-05-09; US2006-844100P Applic. Date: 2006-09-11

Inventor: BEGOVICH ANN [US]; BEASLEY ELLEN [US]; CARGILL MICHELE [US]; SCHRODI STEVEN [US]


Application No.: US20130225478A1  Published: 29/Aug/2013

Title: PEPTIDES BASED ON THE TRANSMEMBRANE DOMAIN OF A TOLL-LIKE RECEPTOR (TLR) FOR TREATMENT OF TLR-MEDIATED DISEASES

Applicant/Assignee: YEDA RESEARCH AND DEVELOPMENT CO. LTD

Application No.: 13/811226   Filing Date: 19/Jul/2011

Abstract:

Peptides are provided that are capable of inhibiting cell activation mediated by a Toll-like receptor (TLR) selected from TLR 1, 2, 4 or 6, said peptide comprising a sequence consisting of, or found within, the sequence of the transmembrane domain of a TLR selected from TLR 1, 2, 4 or 6 and optionally cytoplasmic and extracellular regions flanking the transmembrane domain. These peptides as well as pharmaceutical composition comprising them are useful for the treatment of TLR-mediated disease.

Priority: US2010-365559P Applic. Date: 2010-07-19; WO2011IL00573 Applic. Date: 2011-07-19

Inventor: SHAI YECHIEL [IL]; FINK AVNER [IL]; REUVEN ELIRAN-MOSHE [IL]; SHMUEL-GALIA LIRAZ [IL]


Application No.: US20130225501A1  Published: 29/Aug/2013

Title: SKIN COLLAGEN PRODUCTION-PROMOTING AGENT

Applicant/Assignee: MEGMILK SNOW BRAND CO., LTD

Application No.: 13/876884   Filing Date: 29/Sep/2011

Abstract:

Skin quality is improved by orally administering a cystatin and/or a degraded product of cystatin in an amount of 10 mug/day or more per adult, or applying a composition that includes a cystatin and/or a degraded product of cystatin in an amount of 0.001 to 2 wt % based on a total amount of the composition.

Priority: JP20100222101 Applic. Date: 2010-09-30; WO2011JP72363 Applic. Date: 2011-09-29

Inventor: KATO KEN [JP]; ONO AIKO [JP]; UENO HIROSHI [JP]; UEDA NORIKO [JP]; MATSUYAMA HIROAKI [JP]


Application No.: US20130231291A1  Published: 05/Sep/2013

Title: FERMENTED SOYA BASED MIXTURE COMPRISING ISOFLAVONES- AGLICONES, EQUOL AND LUNASIL, PROCESS FOR THE PREPARATION AND USES THEREOF IN FOOD, MEDICAL AND COSMETIC FIELDS

Applicant/Assignee:

Application No.: 13/806746   Filing Date: 11/Jul/2011

Abstract:

The present invention concerns a mixture comprising isoflavones-aglicones, such as daidzein, genistein and glycitein, in addition to equol and lunasin, said mixture being based on soya fermented using lactic acid bacteria isolated from food matrices and use of said mixture for protection of skin and similar and of human intestinal cells with particular reference to prevention of inflammatory state and protection of barrier functions and hair loss treatment.

Priority: IT2010RM00378 Applic. Date: 2010-07-12; WO2011IT00240 Applic. Date: 2011-07-11

Inventor: GIULIANI GIAMMARIA [IT]; BENEDUSI ANNA [IT]; GOBBETTI MARCO [IT]; DI CAGNO RAFFAELLA [IT]; BARONI SERGIO [IT]; RIZZELLO CARLO GIUSEPPE [IT]


Application No.: US20130243797A1  Published: 19/Sep/2013

Title: COMPOSITION COMPRISING HYDROLYSED PROTEINS AND OLIGISACCHARIDES FOR TREATING SKIN DISEASES

Applicant/Assignee:

Application No.: 13/988988   Filing Date: 21/Nov/2011

Abstract:

The invention discloses a composition comprising at least one N-acetyl lactosamine, at least one sialylated oligosaccharide and at least one fucosylated oligosaccharide, and a hydrolysate comprising partially and/or extensively hydrolysed proteins, for use in the prevention and/or treatment of skin conditions and skin diseases. Preferably said composition is a starter infant formula. Said skin disease is in particular atopic dermatitis.

Priority: EP20100192229 Applic. Date: 2010-11-23; WO2011EP70562 Applic. Date: 2011-11-21

Inventor: SPRENGER NORBERT [CH]


Application No.: US20130244948A1  Published: 19/Sep/2013

Title: COMPOSITIONS OF CELLS, MEDIA, AND METHODS THEREOF

Applicant/Assignee: SCHARP TECHNOLOGIES, INC

Application No.: 13/843034   Filing Date: 15/Mar/2013

Abstract:

The disclosure provides a composition that comprises co-culture of small embryonic-like stem cells and mesenchymal stem cells, where cell media is reduced or lacking in exogenously supplied growth factors, as well as compositions of growth media that result from, or are manufactured by, co-culture of at least two types of different cells. Also provided are methods for selecting cell media that meet criteria pertaining to cell migration (gap assays) and to confluence.

Priority: US201261611508P Applic. Date: 2012-03-15

Inventor: SCHARP DAVID W [US]


Application No.: US20130251651A1  Published: 26/Sep/2013

Title: Fetal Skin Cell Protein Compositions For The Treatment Of Skin Conditions, Disorders Or Diseases And Methods Of Making And Using The Same

Applicant/Assignee: NEOGYN, INC

Application No.: 13/893048   Filing Date: 13/May/2013

Abstract:

The present invention provides methods and compositions designed for treating a subject suffering from skin conditions, disorders or diseases. The compositions include fetal skin cell proteins obtained from fetal skin cells after induced cell lysis.

Priority: US2010-710437 Applic. Date: 2010-02-23; US2005-226558 Applic. Date: 2005-09-14; US2004-610613P Applic. Date: 2004-09-15; US2005-641067P Applic. Date: 2005-01-03

Inventor: LAURENT-APPLEGATE LEE [CH]; HOHLFELD PATRICK [CH]


Application No.: US20130251660A1  Published: 26/Sep/2013

Title: SKIN WETTING COMPOSITIONS AND METHODS

Applicant/Assignee: ADVANCED BIOCATALYTICS CORP

Application No.: 13/850931   Filing Date: 26/Mar/2013

Abstract:

Disclosed are skin wetting and penetrating compositions and methods, where the compositions comprise the following, or combinations thereof: a surfactant, yeast exo-proteins, a stabilizer, and optionally an oil, humectant, or dermatological active agent.

Priority: US201261615635P Applic. Date: 2012-03-26

Inventor: GOLDFELD MICHAEL G [US]; MICHALOW ANDREW H [US]; PODELLA CARL W [US]; BALDRIDGE JOHN W [US]


Application No.: US20130251821A1  Published: 26/Sep/2013

Title: VEGF-ACTIVATED FAS LIGANDS

Applicant/Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Application No.: 13/655142   Filing Date: 18/Oct/2012

Abstract:

The present invention provides fusion proteins comprising an extracellular domain of a VEGF receptor and a death ligand. The fusion proteins bind to VEGF and to death receptors on tumor cells thereby inhibiting VEGF activation of VEGF receptors and inducing apoptosis in the tumor cells. Fusion proteins of the present invention are useful for inducing apoptosis and cytotoxic effects in cells, treating cancer and diseases or disorders related to unregulated angiogenesis and/or vasculogenesis. Thus, this invention further provides methods for treating angiogenesis related diseases using the fusion proteins, polynucleotides encoding the fusion proteins, vectors containing the polynucleotides, pharmaceutical compositions and kits containing the fusion proteins or the polynucleotides encoding the fusion proteins.

Priority: US2008-063897 Applic. Date: 2008-02-15; WO2006US31991 Applic. Date: 2006-08-15; US2005-708723P Applic. Date: 2005-08-15

Inventor: QUINN TIMOTHY P [US]


Application No.: US20130267463A1  Published: 10/Oct/2013

Title: PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING TH17-MEDIATED DISEASE COMPRISING POLY-GAMMA-GLUTAMIC ACID

Applicant/Assignee: INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY

Application No.: 13/678225   Filing Date: 15/Nov/2012

Abstract:

Provided are a pharmaceutical use of poly-gamma-glutamic acid used for preventing or treating Th17-mediated diseases, a composition for preventing or treating Th17-mediated diseases comprising poly-gamma-glutamic acid as an active ingredient, and a method of preventing or treating Th17-mediated diseases using the same. The pharmaceutical composition is effective in inhibiting the differentiation of Th17 cells while promoting Treg cells, and, thus, can be useful in preventing or treating Th17-mediated diseases such as multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, Crohn's disease, ankylosing spondylitis, and the like.

Priority: KR20120037414 Applic. Date: 2012-04-10

Inventor: YOUN JEEHEE [KR]; KIM TAE-HWAN [KR]; LEE KYUHEON [KR]


Application No.: US20130267471A1  Published: 10/Oct/2013

Title: Formulations and methods of use for alpha connexin C-terminal (ACT) peptides

Applicant/Assignee:

Application No.: 13/815723   Filing Date: 15/Mar/2013

Abstract:

This invention relates to a topical gel drug product preparation containing a composition comprising an isolated polypeptide having a carboxy-terminal amino acid sequence of an alpha connexin (ACT peptide), peptide stabilizers, excipients, buffering agents, and the like. A formulation and preparation steps are disclosed for the manufacturing of a stable, elegant, and pourable topical gel. The resulting formulation possesses long term stability suitable for aesthetic as well as therapeutic applications including the prevention of scaring and accelerated healing of wounds. Methods for treatment of chronic wounds, including chronic ulcers, are also provided.

Priority: WO2013US28727 Applic. Date: 2013-03-01; US201261605528P Applic. Date: 2012-03-01

Inventor: GHATNEKAR GAUTAM [US]; ELSTROM TUAN [US]


Application No.: US20130274197A1  Published: 17/Oct/2013

Title: BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS

Applicant/Assignee:

Application No.: 13/910778   Filing Date: 05/Jun/2013

Abstract:

The present invention provides a family of benzodiazepinone compounds and pharmaceutical compositions thereof. The present invention also provides methods of treating certain skin conditions, e.g., atopic dermatitis, rosacea, or psoriasis, by administering a benzodiazepinone and methods of reducing the proliferation of keratinocyte cells by exposing such cells to a benzodiazepinone.

Priority: US201113283231 Applic. Date: 2011-10-27; US2008-266239 Applic. Date: 2008-11-06; US2007-985898P Applic. Date: 2007-11-06

Inventor: GLICK GARY D [US]


Application No.: US20130280189A1  Published: 24/Oct/2013

Title: PERSONAL CARE AND HEALTH CARE COMPOSITIONS

Applicant/Assignee: DOW CORNING FRANCE SAS, DOW CORNING CORPORATION

Application No.: 13/994864   Filing Date: 09/Jan/2012

Abstract:

The present invention relates to topical compositions comprising a non adhesive film forming silicone acrylate hybrid composition, at least one physiologically acceptable ingredient and at least one physiologically acceptable solvent. Such non adhesive film forming silicone acrylate hybrid compositions tend to provide comfortable films for topical compositions.

Priority: US201161431165P Applic. Date: 2011-01-10; WO2012IB00249 Applic. Date: 2012-01-09

Inventor: THOMAS XAVIER JEAN-PAUL [FR]; MITCHELL TIMOTHY [US]


Application No.: US20130287834A1  Published: 31/Oct/2013

Title: ANTI-ADHERENT FORMULATION INCLUDING A CATIONIC OR NONIONIC ACRYLATE CO-POLYMER

Applicant/Assignee:

Application No.: 13/460313   Filing Date: 30/Apr/2012

Abstract:

Liquid formulations having anti-adherent properties are disclosed herein. The liquid anti-adherent formulation described herein acts to prevent the adherence of menses and/or fecal material to the skin in the labial and perianal regions during and after menstruation or defecation, respectively. The liquid anti-adherent formulation contains a carrier, a polymer selected from a nonionic acrylate co-polymer, cationic acrylate co-polymer, and combinations thereof. Anti-adherent formulation is found to be effective if a menses leave-on percentage as defined within the Menses Leave-On Percentage Test method described herein was less than 6.2% after two insults.

Priority:

Inventor: HOFFMAN DOUGLAS R [US]; CUNNINGHAM COREY T [US]; MUNDSCHAU STACY A [US]; KOENIG DAVID W [US]; DONG SHAOSHENG [US]


Application No.: US20130288964A1  Published: 31/Oct/2013

Title: Use of peptides for promoting wound healing

Applicant/Assignee: VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PA

Application No.: 13/827384   Filing Date: 14/Mar/2013

Abstract:

The current invention relates to the use of a peptide comprising an amino acid sequence in the preparation of a medicament for the regeneration of tissue, preferably for the treatment of a wound. Further the invention relates to compositions comprising such peptides, and use of said peptides in both medical and nonmedical (cosmetic) applications.

Priority: EP20080075012 Applic. Date: 2008-01-07

Inventor: BOLSCHER JOHANNES GERHARDUS MARIA [NL]; VAN NIEUW AMERONGEN ARIE [NL]; VEERMAN ENGELMUNDUS CORNELIS IGNATIUS [NL]; OUDHOFF MENNO JOHANNES [NL]; VAN T HOF WILLEM [NL]; NAZMI KAMRAN [NL]; VAN DEN KEIJBUS PETRONELLA ADRIANA MARIA [NL]


Application No.: US20130295037A1  Published: 07/Nov/2013

Title: IN SITU BONDS

Applicant/Assignee: PROMETHEANSURGICAL DEVICES, LLC

Application No.: 13/934788   Filing Date: 03/Jul/2013

Abstract:

A biocompatible tissue-bonding adhesive composition having a polyol of functionality N. The polyol being terminated has at least one polyisocyanate in solution with at least (N-1) % of the solution having free polyisocyanate. N may be in the range 1.5-8. The polyol may be a branched polypropylene/polyethylene oxide copolymer.

Priority: US2001-020331 Applic. Date: 2001-12-12

Inventor: MILBOCKER MICHAEL T [US]


Application No.: US20130295038A1  Published: 07/Nov/2013

Title: Cross-Linked Copolymer Containing Phosphorylcholine Monomer and Cosmetic Composition Containing Same

Applicant/Assignee: KCI LIMITED

Application No.: 13/978625   Filing Date: 23/Nov/2011

Abstract:

Disclosed is a copolymer containing an alpha,beta-ethylenically unsaturated monomer, a phosphorylcholine monomer, and a cross-linking agent as a monomer. Also disclosed are a cosmetic composition containing the copolymer and a cosmetic material using the cosmetic composition.

Priority: KR20110001978 Applic. Date: 2011-01-07; KR20110122960 Applic. Date: 2011-11-23; WO2011KR08989 Applic. Date: 2011-11-23

Inventor: KIM YONG CHUL [KR]; KIM HYEONG BAE [KR]; HAN IN SUN [KR]; WANG SE KWAN [KR]; PARK JUNG HO [KR]


Application No.: US20130296239A1  Published: 07/Nov/2013

Title: Material for Wound Healing and Skin Reconstruction

Applicant/Assignee: 3-D MATRIX, LTD

Application No.: 13/724519   Filing Date: 21/Dec/2012

Abstract:

The invention relates to a material for wound healing and skin reconstruction containing a peptide, wherein the peptide is a self-assembling peptide which is an amphiphilic peptide having 8 to 200 amino acid residues with periodic repeats of alternating hydrophilic amino acids and hydrophobic amino acids, and forms a stable beta-sheet structure in an aqueous solution in the presence of a monovalent ion. The material for wound healing and skin reconstruction of the present invention is capable of healing a wound area of mammals quicker than spontaneous recovery without leaving any scars, wherein the material has no potential risk of infectious disease such as virus transmission.

Priority: JP20070314640 Applic. Date: 2007-12-05; US2010-746520 Applic. Date: 2010-07-08; WO2008JP72047 Applic. Date: 2008-12-04

Inventor: TAKAMURA KENTARO [JP]; TAKEI JIRO [JP]


Application No.: US20130316942A1  Published: 28/Nov/2013

Title: Antioxidant, Anti-Inflammatory, Anti-Radiation, Metal Chelating Compounds And Uses Thereof

Applicant/Assignee:

Application No.: 13/963537   Filing Date: 09/Aug/2013

Abstract:

The present invention relates to potent compounds having combined antioxidant, anti-inflammatory, anti-radiation and metal chelating properties. Specifically, the present invention relates to short peptides having these properties, and to methods and uses of such short peptides in clinical and cosmetic applications.

Priority: US201313947744 Applic. Date: 2013-07-22; WO2012IL00032 Applic. Date: 2012-01-19; US201161469138P Applic. Date: 2011-03-30; US201161434454P Applic. Date: 2011-01-20

Inventor: MOGRABI JOSEF [IL]; ATLAS DAPHNE [IL]; KEYNAN SHOSHANA [IL]


Application No.: US20130316955A1  Published: 28/Nov/2013

Title: AMINOSTATIN DERIVATIVES FOR THE TREATMENT OF ARTHROSIS

Applicant/Assignee: MERCK PATENT GMBH

Application No.: 13/983848   Filing Date: 09/Jan/2012

Abstract:

The present invention relates to compounds of the formula (I) and in particular medicaments comprising at least one compound of the formula (I) for use in the treatment and/or prophylaxis of physiological and/or pathophysiological states in the triggering of which cathepsin D is involved, in particular for use in the treatment and/or prophylaxis of arthrosis, traumatic cartilage injuries, arthritis, pain, allodynia or hyperalgesia.

Priority: EP20110000974 Applic. Date: 2011-02-08; WO2012EP00069 Applic. Date: 2012-01-09

Inventor: KLEIN MARKUS [DE]; TSAKLAKIDIS CHRISTOS [DE]; GUEHRING HANS [DE]; LEUTHNER BRIGITTA [DE]


Application No.: US20130316956A1  Published: 28/Nov/2013

Title: NUCLEIC ACIDS ENCODING PEPTIDES FOR TREATING WOUNDS, ANTI-ANGIOGENIC COMPOUNDS AND USES THEREOF

Applicant/Assignee: TRUSTEES OF TUFTS COLLEGE

Application No.: 13/919370   Filing Date: 17/Jun/2013

Abstract:

The present disclosure relates to protein and peptide chemistry. More particularly, it relates to compounds, compositions and uses thereof for promoting and inhibiting angiogenesis. The peptides of the present disclosure include peptides comprising SEQ ID NOs: 1-4 which promote angiogenesis and cell proliferation. Further, the anti-angiogenic compounds of the present disclosure include antisense oligonucleotides that hybridize or are complementary to the polynucleotides of SEQ ID NOs: 5-16, and the like.

Priority: US201113126145 Applic. Date: 2011-04-26; WO2009US62187 Applic. Date: 2009-10-27; US2008-197420P Applic. Date: 2008-10-27

Inventor: HERMAN IRA M [US]


Application No.: US20130317416A1  Published: 28/Nov/2013

Title: STERILE LIQUID COMPOSITION FOR FILLING WRINKLES

Applicant/Assignee: L'OREAL

Application No.: 13/996179   Filing Date: 20/Dec/2011

Abstract:

The subject matter of the present invention is a sterile liquid composition dedicated to administration into or through the skin and/or the lips, wherein said composition comprises, in a physiologically acceptable medium, at least one photo-crosslinkable compound, wherein said compound comprises at least one activated photo-dimerizable group having at least one activated double bond and selected from photo-dimerizable groups carrying a stilbazolium function of formula (Ia) or (Ib) and wherein the photo-dimerizable groups carry a styrylazolium function of formula (II), the photo-dimerizable group(s) being carried by a partially or totally hydrolysed poly(vinyl acetate) polymer, a polysaccharide or a polyvinyl alcohol

Priority: FR20100060788 Applic. Date: 2010-12-20; US201161441757P Applic. Date: 2011-02-11; WO2011IB55806 Applic. Date: 2011-12-20

Inventor: SAMAIN HENRI [FR]; SIMONNET JEAN-THIERRY [FR]


Application No.: US20130323187A1  Published: 05/Dec/2013

Title: SYNTHETIC PEPTIDES FOR USE AS INHIBITORS OF NEUROTRANSMITTER SECRETION AND AS INDUCERS OF CELLULAR RELAXATION

Applicant/Assignee: PARTNERSHIP & CORP. TECHNOLOGY TRANSFER

Application No.: 13/685114   Filing Date: 26/Nov/2012

Abstract:

The present invention describes material and methods related to synthetic peptides which block the secretion of neurotransmitters and induce muscle relaxation, and use of said peptides as inhibitors of neurotransmitter secretion and muscle contraction, and as inducers of muscle relaxation.

Priority: US2008-158775 Applic. Date: 2008-10-17; WO2006EP12501 Applic. Date: 2006-12-22; US2005-753607P Applic. Date: 2005-12-23

Inventor: FASEL NICOLAS [CH]; KUENDIG AMAL [CH]


Application No.: US20130324458A1  Published: 05/Dec/2013

Title: METHODS AND COMPOSITIONS USING KLOTO-FGF FUSION POLYPEPTIDES

Applicant/Assignee:

Application No.: 13/904574   Filing Date: 29/May/2013

Abstract:

The present invention is directed to methods, kits and compositions for preventing or treating age-related conditions or metabolic disorders. The Klotho fusion polypeptides of the invention include at least a Klotho protein or an active fragment thereof. In one embodiment, the fusion polypeptide comprises a Klotho polypeptide, a FGF (such as FGF23) and (optionally) a modified Fc fragment. The Fc fragment can, for example, have decreased binding to Fc-gamma-receptor and increased serum half-life. The Klotho fusion proteins are useful in the treatment and prevention of a variety of age-related conditions and metabolic disorders. In another embodiment, the fusion polypeptide comprises a FGF (such as FGF23) and a modified Fc fragment.

Priority: US2009-360970 Applic. Date: 2009-01-28; US2008-063015P Applic. Date: 2008-01-28

Inventor: GLASS DAVID [US]; HU SHOU-IH [US]


Application No.: US20130325062A1  Published: 05/Dec/2013

Title: TISSUE ADHESIVE BASED ON NITROGEN-MODIFIED ASPARTATES

Applicant/Assignee: BAYER INTELLECTUAL PROPERTY GMBH

Application No.: 13/984186   Filing Date: 06/Feb/2012

Abstract:

The invention relates to a polyurea system comprising as component A) isocyanate-functional prepolymers which can be obtained by reacting aliphatic isocyanates A1) with polyols A2) that can have a number-average molecular weight of =400 g/mol and an average OH functionality of 2 to 6 in particular

and as component B) amino-functional aspartic acid esters of the general formula (I) in which X is an organic group containing a secondary amino function, R1, R2 are the same or different organic groups that do not have Zerewitinoff-active hydrogen, and n is a whole number of at least 2, in particular for sealing, bonding, gluing, or covering cell tissue. The invention also relates to a metering system for the polyurea system according to the invention.

Priority: EP20110153810 Applic. Date: 2011-02-09; WO2012EP51914 Applic. Date: 2012-02-06

Inventor: HECKROTH HEIKE [DE]; EGGERT CHRISTOPH [DE]


Application No.: US20130331331A1  Published: 12/Dec/2013

Title: HEXAPEPTIDE WITH IMPROVED ACTIVITY IN THE REPAIR OF CELLULAR DNA OF DERMAL CELLS

Applicant/Assignee:

Application No.: 13/984341   Filing Date: 13/Feb/2012

Abstract:

The present invention relates to a compound having a structure selected from: Ac-Nle-Glu-His-D-Phe-Arg-Trp-NH2 (SEQ ID NO: 1)

or Ac-Nle-Gln-His-D-Phe-Arg-Trp-NH2 (SEQ ID NO: 2) or a pharmaceutically acceptable salt thereof. The compound of the salt thereof are particularly useful for the repair or prevention of damage of cellular DNA of dermal (skin) cells following UV irradiation in a mammal.

Priority: EP20110541959 Applic. Date: 2011-02-11; WO2012EP52416 Applic. Date: 2012-02-13

Inventor: WOLGEN PHILIPPE [AU]


Application No.: US20130336882A1  Published: 19/Dec/2013

Title: ADHESIVE COMPOSITION FOR SOFT TISSUES, ADHESIVE COMPOSITION FOR WOUND DRESSING OR WOUND DRESSING COMPOSITION

Applicant/Assignee: MITSUI CHEMICALS, INC

Application No.: 13/966912   Filing Date: 14/Aug/2013

Abstract:

The adhesive composition for soft tissues, the adhesive composition for wound dressing or the wound dressing agent composition of the present invention is an adhesive composition for soft tissues, an adhesive composition for wound dressing or a wound dressing agent composition, comprising a monomer (A), a polymer (B) and a polymerization initiator composition (C) containing an organoboron compound, and is characterized by having a viscosity of 0.4 to 75,000 cp within 30 seconds after mixing of the components (A), (B) and (C). The composition of the present invention not only has low toxicity, low harmfulness and high adhesive strength but also is excellent in workability during application and is capable of forming films of excellent properties.

Priority: JP20090265647 Applic. Date: 2009-11-20; JP20090265649 Applic. Date: 2009-11-20; US201213508009 Applic. Date: 2012-05-03; WO2010JP70546 Applic. Date: 2010-11-18

Inventor: ASADA NORIAKI [JP]; AOKI SHINYA [JP]; NARUSE HIROSHI [JP]; MIYAKOSHI SHOICHI [JP]; ARATA MASAMI [JP]


Application No.: US20130338067A1  Published: 19/Dec/2013

Title: Fusion Polypeptides Comprising an Active Protein Linked to a Mucin-Domain Polypeptide

Applicant/Assignee: ALKERMES, INC

Application No.: 13/911818   Filing Date: 06/Jun/2013

Abstract:

The present invention provides fusion proteins comprising a mucin-domain polypeptide covalently linked to an active protein that has improved properties (e.g. pharmacokinetic and/or physicochemical properties) compared to the same active protein not linked to mucin-domain polypeptide, as well as methods for making and using the fusion proteins of the invention.

Priority: US201261657264P Applic. Date: 2012-06-08; US201361778575P Applic. Date: 2013-03-13; US201261657378P Applic. Date: 2012-06-08; US201261723081P Applic. Date: 2012-11-06; US201261657285P Applic. Date: 2012-06-08; US201361778812P Applic. Date: 2013-03-13

Inventor: ALVAREZ JUAN [US]; CHAMOUN JEAN [US]; LOSEY HEATHER C [US]


Application No.: US20130344121A1  Published: 26/Dec/2013

Title: COSMETIC COMPOSITION FOR MAKE-UP CONTAINING SILICONE ELASTOMER

Applicant/Assignee: COSMAX CO., LTD

Application No.: 14/003889   Filing Date: 09/Mar/2012

Abstract:

Disclosed is an elastic make-up cosmetic composition containing a silicone elastomer. More particularly, the make-up cosmetic composition includes a powder type silicone elastomer, powder extender pigment, hydrocarbon gel, anhydrous silicone oil and organic dispersant oil. A silicone elastomer of a surface-treated powder type and a polymer are used to improve the dispersibility of silicone elastomer when producing a cosmetic composition. As a result, it is possible to provide a make-up cosmetic composition having a silky and soft elastic feel. The resultant cosmetic composition is adhered to the skin smoothly, has a good elastic feel and spreadability and shows little dust flying.

Priority: KR20110021639 Applic. Date: 2011-03-11; WO2012KR01738 Applic. Date: 2012-03-09

Inventor: KIM SUNG YONG [KR]; BAE JEONG HO [KR]; PARK MYEONG SAM [KR]

Clck to enlarge and view details
   
US Patent Applications  in 2012
...or use our Search Engine to
search for patent documents by
number.
Search for anything. Simply
type the words in the box..